The Heart Closure Devices Market has witnessed substantial growth over the past few years, driven by the increasing prevalence of congenital heart diseases, rising demand for minimally invasive ...

transcatheter closure of atrial septal defects (ASD) or patent foramen ovale (PFO) was introduced into clinical practice. Objective: To investigate the functional effects on heart valves caused by an ...

Doctor Mahesh said the procedure was possible through his guidance and the arrival of devices. “It’s a minimally invasive procedure. So we try to put a mesh, umbrella kind of mesh into the heart, ...

various attempts have been made to develop biodegradable devices for CHD closure. To our knowledge, the Pansy® PFO occluder is the first biodegradable PFO occluder to be used in the human body. Due to ...

Introduction: Transcatheter device closure of ventricular septal defects (VSDs) offers an appealing and effective alternative to surgical repair. The Lifetech™ Konar-Multifunctional Occluder (MFO) VSD ...

Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through ...

Tennessee lawmakers considered several bills that directly affect students in the session that just ended. Here’s a roundup ...

CHARLOTTE, N.C., March 27, 2025 /PRNewswire/ -- Vasorum USA, Inc, a privately held, commercial-stage medical device company dedicated to redefining vascular closure, today announced U.S. Food and Drug ...

CHARLOTTE, N.C., March 27, 2025 /PRNewswire/ -- Vasorum USA, Inc, a privately held, commercial-stage medical device company dedicated to redefining vascular closure, today announced U.S. Food and ...

The company stated it plans to launch PerQseal Elite in select European markets in Summer 2025. According to the company, the PerQseal Elite is a sutureless and fully bioresorbable large-bore vessel ...